Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, 7 February 2015, Vol 294, No 7848

Sort by: Newest first Oldest first A-Z Z-A

  • A range of anti-smoking policies and new cessation products has led to reduced rates of smoking in most countries, which will eventually impact on smoking-related deaths.

    A decade of smoking cessation in Europe Subscription

    5 FEB 2015 By Dawn Connelly

    The continent with the worst smoking habit is gradually giving it up. A range of anti-smoking policies and new cessation products has led to reduced rates of smoking in most countries, which will eventually impact on smoking-related deaths.

  • Foods high in salt, sugar and fat should be taxed to discourage unhealthy eating and slow rates of childhood obesity

    A tax on junk food is the way to fight the childhood obesity crisis Subscription

    5 FEB 2015 11:03 By Colin Michie
    Comments (1)

    Foods high in salt, sugar and fat should be taxed to discourage unhealthy eating and slow rates of childhood obesity, says Colin Michie.

  • Adherence to glucose lowering therapies in diabetes patients falls following a cancer diagnosis, new research finds

    Adherence to diabetes treatments falls after a cancer diagnosis Subscription

    3 FEB 2015 12:22

    Adherence to glucose lowering therapies in diabetes patients falls following a cancer diagnosis.

  • Anti-VEGF (vascular endothelial growth factor) therapies could help treat tuberculosis, research finds. In the image, SEM of tuberculosis bacteria.

    Anti-VEGF therapies could have role in treating TB Subscription

    3 FEB 2015 13:28

    Bevacizumab, an anti-VEGF drug, was able to normalise granuloma vasculature, improve the delivery of small molecules and decrease hypoxia in a rabbit model of tuberculosis.

  • Breakyl side effects

    3 FEB 2015 13:27

    The summary of product characteristics of Breakyl (fentanyl: Meda) has been updated to include the following adverse reactions: fall, flushing and hot flush, diarrhoea, fatigue, respiratory depression, malaise, peripheral oedema, convulsion, hallucination. In addition it is now contraidndicated in treatment of acute pain other than breakthrough pain.

  • Calcium-Sandoz syrup discontinued

    30 JAN 2015 17:04

    Calcium-Sandoz Syrup (calcium glubionate 1.09g and calcium lactobionate 0.727g per 5ml) has been discontinued in the UK by Alliance Pharmaceuticals and there is no remaining stock available. Calcium-Sandoz Syrup has not been readily available in the UK for over one year due manufacturing issues that have been unable to be resolved. Further information on +44 (01)249 466966. 

  • Cholic acid named ‘Golden Pill’ in Prescrire’s annual awards Subscription

    2 FEB 2015 16:44

    ‘A drug used to treat children with a rare genetic condition who are unable to produce bile and risk fatal liver failure has received international recognition.

  • Dementia link to common medicines Subscription

    30 JAN 2015 11:45

    28 January 2015: A report was published which links commonly used medicines, including some over-the-counter treatments, to dementia. RPS English pharmacy board chair David Branford was interviewed by LBC Radio and Channel 5 News.

  • Eculizumab — with £340,200 price tag — gets go ahead from NICE Subscription

    28 JAN 2015 11:53

    Eculizumab, dubbed “the world’s most expensive drug”, is being made available on the NHS in England following guidance from the National Institute for Health and Care Excellence.

  • Eculizumab approved by NICE Subscription

    30 JAN 2015 16:37

    The National Institute for Health and Care Excellence approved the use of eculizumab (Soliris) for the treatment of atypical haemolytic uraemic syndrome (aHUS) for NHS patients in England on 27 January 2015. But conditions were attached: the product should be made available through an expert centre, the number of people diagnosed with aHUS and those being treated with eculizumab must be recorded and monitored, a national clinical protocol should be established for starting and stopping ...

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.